Findings show afatinib 30 mg provides better tolerability and similar efficacy in lung cancer, suggesting a safer option for treatment.
Afatinib 30 mg daily achieved comparable efficacy and better tolerability than 40 mg, with significantly longer PFS and OS in patients harboring compound or double-rare EGFR mutations. These findings suggest that lower-dose afatinib may optimize efficacy and safety in patients with uncommon EGFR-mutant NSCLC.
No takes yet. Share an insight, caveat, or question.
Hung et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: